PATENT CLAIM ANALYSIS

Application Number: 15942802
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["514", "230500"]

Abstract:
The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone dependent diseases and gynaecological diseases in particular Endometriosis or Uterine Fibroids (UF), as a sole agent or in combination with other active ingredients wherein circulating endogenous estradiol concentration of treated women is maintained to a level in a range of 40 pg/mL to 85 pg/mL.

Claim (Index 5):
The Selective Progesterone Receptor Modulator (SPRM) according to  claim 1  independently from each other wherein the treatment period is defined as a period where Compound 1 is continuously administered during a period of four (4) weeks to one (1) year and optionally the treatment period is followed by a break period where administration of Compound 1 is discontinued until one (1) or two (2) menstrual bleeding episodes occur and treatment period and break period as defined above are repeated at least one (1) time.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.33846
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13855559', '12990203', '14440023', '14251192', '12446567']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7942087904524016
- 35 USC 102 Novelty (BERT): 0.5284318334895128
- Combined Prediction Score: 0.7676310947561128
- Mean Citation Score: 317.07148400000005
- Max Citation Score: 345.38397000000015
- Similarity Product: 254.44719048801903

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test